Zoledronic acid oral - Merrion

Drug Profile

Zoledronic acid oral - Merrion

Alternative Names: MER-101; Orazol

Latest Information Update: 10 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merrion Pharmaceuticals
  • Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
  • Mechanism of Action Geranyltranstransferase inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Bone metastases

Most Recent Events

  • 10 Sep 2015 No recent reports on development identified - Phase-II for Bone metastases in USA, Estonia and Latvia (PO)
  • 16 Nov 2010 Zoledronic acid oral is still in phase II trials in USA
  • 20 Oct 2009 Pharmacokinetics data from a clinical trial released by Merrion Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top